Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration

Jaeryung Kim, Jang Ryul Park, Jeongwoon Choi, Intae Park, Yoonha Hwang, Hosung Bae, Yongjoo Kim, Woo Jhon Choi, Jee Myung Yang, Sangyeul Han, Tae Young Chung, Pilhan Kim, Yoshiaki Kubota, Hellmut G. Augustin, Wang Yuhl Oh, Gou Young Koh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade for NV-AMD has shown beneficial outcomes, unmet medical needs for patients refractory or tachyphylactic to anti-VEGF therapy exist. In addition, the treatment could exacerbate choriocapillary rarefaction, necessitating advanced treatment for fundamental recovery from NV-AMD. In this study, Tie2 activation by angiopoietin-2–binding and Tie2-activating antibody (ABTAA) presents a therapeutic strategy for NV-AMD. Conditional Tie2 deletion impeded choriocapillary maintenance, rendering eyes susceptible to NV-AMD development. Moreover, in a NV-AMD mouse model, ABTAA not only suppressed choroidal neovascularization (CNV) and vascular leakage but also regenerated the choriocapillaris and relieved hypoxia. Conversely, VEGF blockade degenerated the choriocapillaris and exacerbated hypoxia, although it suppressed CNV and vascular leakage. Together, we establish that angiopoietin-Tie2 signaling is critical for choriocapillary maintenance and that ABTAA represents an alternative, combinative therapeutic strategy for NV-AMD by alleviating anti-VEGF adverse effects.

Original languageEnglish
Article numbereaau6732
JournalScience Advances
Volume5
Issue number2
DOIs
Publication statusPublished - 2019 Feb 13

Fingerprint

degeneration
regeneration
activation
antibodies
angiogenesis
hypoxia
maintenance
leakage
rarefaction
deletion
refractories
mice
therapy
recovery
causes

ASJC Scopus subject areas

  • Physics and Astronomy (miscellaneous)

Cite this

Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration. / Kim, Jaeryung; Park, Jang Ryul; Choi, Jeongwoon; Park, Intae; Hwang, Yoonha; Bae, Hosung; Kim, Yongjoo; Choi, Woo Jhon; Yang, Jee Myung; Han, Sangyeul; Chung, Tae Young; Kim, Pilhan; Kubota, Yoshiaki; Augustin, Hellmut G.; Oh, Wang Yuhl; Koh, Gou Young.

In: Science Advances, Vol. 5, No. 2, eaau6732, 13.02.2019.

Research output: Contribution to journalArticle

Kim, J, Park, JR, Choi, J, Park, I, Hwang, Y, Bae, H, Kim, Y, Choi, WJ, Yang, JM, Han, S, Chung, TY, Kim, P, Kubota, Y, Augustin, HG, Oh, WY & Koh, GY 2019, 'Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration', Science Advances, vol. 5, no. 2, eaau6732. https://doi.org/10.1126/sciadv.aau6732
Kim, Jaeryung ; Park, Jang Ryul ; Choi, Jeongwoon ; Park, Intae ; Hwang, Yoonha ; Bae, Hosung ; Kim, Yongjoo ; Choi, Woo Jhon ; Yang, Jee Myung ; Han, Sangyeul ; Chung, Tae Young ; Kim, Pilhan ; Kubota, Yoshiaki ; Augustin, Hellmut G. ; Oh, Wang Yuhl ; Koh, Gou Young. / Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration. In: Science Advances. 2019 ; Vol. 5, No. 2.
@article{b4332543571c4e9aa4e8dbd39265253f,
title = "Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration",
abstract = "Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade for NV-AMD has shown beneficial outcomes, unmet medical needs for patients refractory or tachyphylactic to anti-VEGF therapy exist. In addition, the treatment could exacerbate choriocapillary rarefaction, necessitating advanced treatment for fundamental recovery from NV-AMD. In this study, Tie2 activation by angiopoietin-2–binding and Tie2-activating antibody (ABTAA) presents a therapeutic strategy for NV-AMD. Conditional Tie2 deletion impeded choriocapillary maintenance, rendering eyes susceptible to NV-AMD development. Moreover, in a NV-AMD mouse model, ABTAA not only suppressed choroidal neovascularization (CNV) and vascular leakage but also regenerated the choriocapillaris and relieved hypoxia. Conversely, VEGF blockade degenerated the choriocapillaris and exacerbated hypoxia, although it suppressed CNV and vascular leakage. Together, we establish that angiopoietin-Tie2 signaling is critical for choriocapillary maintenance and that ABTAA represents an alternative, combinative therapeutic strategy for NV-AMD by alleviating anti-VEGF adverse effects.",
author = "Jaeryung Kim and Park, {Jang Ryul} and Jeongwoon Choi and Intae Park and Yoonha Hwang and Hosung Bae and Yongjoo Kim and Choi, {Woo Jhon} and Yang, {Jee Myung} and Sangyeul Han and Chung, {Tae Young} and Pilhan Kim and Yoshiaki Kubota and Augustin, {Hellmut G.} and Oh, {Wang Yuhl} and Koh, {Gou Young}",
year = "2019",
month = "2",
day = "13",
doi = "10.1126/sciadv.aau6732",
language = "English",
volume = "5",
journal = "Indian Journal of Pure and Applied Physics",
issn = "0019-5596",
publisher = "National Institute of Science Communication and Information Resources (NISCAIR)",
number = "2",

}

TY - JOUR

T1 - Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration

AU - Kim, Jaeryung

AU - Park, Jang Ryul

AU - Choi, Jeongwoon

AU - Park, Intae

AU - Hwang, Yoonha

AU - Bae, Hosung

AU - Kim, Yongjoo

AU - Choi, Woo Jhon

AU - Yang, Jee Myung

AU - Han, Sangyeul

AU - Chung, Tae Young

AU - Kim, Pilhan

AU - Kubota, Yoshiaki

AU - Augustin, Hellmut G.

AU - Oh, Wang Yuhl

AU - Koh, Gou Young

PY - 2019/2/13

Y1 - 2019/2/13

N2 - Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade for NV-AMD has shown beneficial outcomes, unmet medical needs for patients refractory or tachyphylactic to anti-VEGF therapy exist. In addition, the treatment could exacerbate choriocapillary rarefaction, necessitating advanced treatment for fundamental recovery from NV-AMD. In this study, Tie2 activation by angiopoietin-2–binding and Tie2-activating antibody (ABTAA) presents a therapeutic strategy for NV-AMD. Conditional Tie2 deletion impeded choriocapillary maintenance, rendering eyes susceptible to NV-AMD development. Moreover, in a NV-AMD mouse model, ABTAA not only suppressed choroidal neovascularization (CNV) and vascular leakage but also regenerated the choriocapillaris and relieved hypoxia. Conversely, VEGF blockade degenerated the choriocapillaris and exacerbated hypoxia, although it suppressed CNV and vascular leakage. Together, we establish that angiopoietin-Tie2 signaling is critical for choriocapillary maintenance and that ABTAA represents an alternative, combinative therapeutic strategy for NV-AMD by alleviating anti-VEGF adverse effects.

AB - Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade for NV-AMD has shown beneficial outcomes, unmet medical needs for patients refractory or tachyphylactic to anti-VEGF therapy exist. In addition, the treatment could exacerbate choriocapillary rarefaction, necessitating advanced treatment for fundamental recovery from NV-AMD. In this study, Tie2 activation by angiopoietin-2–binding and Tie2-activating antibody (ABTAA) presents a therapeutic strategy for NV-AMD. Conditional Tie2 deletion impeded choriocapillary maintenance, rendering eyes susceptible to NV-AMD development. Moreover, in a NV-AMD mouse model, ABTAA not only suppressed choroidal neovascularization (CNV) and vascular leakage but also regenerated the choriocapillaris and relieved hypoxia. Conversely, VEGF blockade degenerated the choriocapillaris and exacerbated hypoxia, although it suppressed CNV and vascular leakage. Together, we establish that angiopoietin-Tie2 signaling is critical for choriocapillary maintenance and that ABTAA represents an alternative, combinative therapeutic strategy for NV-AMD by alleviating anti-VEGF adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=85061970290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061970290&partnerID=8YFLogxK

U2 - 10.1126/sciadv.aau6732

DO - 10.1126/sciadv.aau6732

M3 - Article

C2 - 30788433

AN - SCOPUS:85061970290

VL - 5

JO - Indian Journal of Pure and Applied Physics

JF - Indian Journal of Pure and Applied Physics

SN - 0019-5596

IS - 2

M1 - eaau6732

ER -